U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CPG Sec. 150.100 Requests for Portions of Intermediate or End Products Resulting from FDA Sample Analysis
  1. Search for FDA Guidance Documents

COMPLIANCE POLICY GUIDE (CPG)

CPG Sec. 150.100 Requests for Portions of Intermediate or End Products Resulting from FDA Sample Analysis March 1988

Final
Issued by:
Guidance Issuing Office
Office of Regulatory Affairs

BACKGROUND:

FDA occasionally receives requests for microbiological cultures isolated from samples analyzed by FDA. Requests for other entities isolated, extracted, or produced by sample analysis, i.e., chemical isolates, extracts, filth debris, etc., may also be received, especially regarding consumer complaint samples.

The Federal Food, Drug, and Cosmetic Act, makes no provision for FDA to provide to requesters portions of end or intermediate products resulting from FDA sample analysis. Section 702(b) of the act provides that, upon request, a part of an official sample of a food, drug, or cosmetic will be provided for examination or analysis to any person named on the label, the owner of the sampled product, or his attorney or agent. This section of the act applies to portions of the sampled commodity. It does not apply to intermediate or end products resulting from sample analysis.

POLICY:

Portions of intermediate or end products resulting from FDA sample analyses will not be routinely provided to requesters from outside the agency, including consumers from whom samples have been collected as part of the complaint investigation.

Exceptions to this policy may be considered when the agency determines that providing portions of intermediate or end products to the requester would help resolve a serious public health matter or would benefit the public wellbeing. When a request appears to warrant such consideration, the request should be referred to the Office of Compliance within the appropriate center for review.

Issued: 3/23/88

Submit Comments

Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All comments should be identified with the title of the guidance.

Back to Top